Colorectal malignancy represents the second most common cause of cancer related mortality in the UK. The majority of mortality relates to metastatic disease, most commonly colorectal liver metastases (CRLM)[@b1].

For several decades it has been recognised that CRLM do not necessarily equate incurable disease. Previous resection criteria required low burden disease limited to one lobe. This is no longer the case; the gloves are off when it comes to liver metastases.

There are two simple criteria for CRLM resection. Resection must be technically feasible with adequate margins and sufficient remnant liver (minimum 30% volume) and the patient must be fit enough to undergo liver resection. Even where there is unlikely to be sufficient remnant volume this does not preclude the possibility for resection. Techniques including chemotherapy to reduce tumour burden, ablation for small lesions and portal vein embolization to produce future liver remnant hypertrophy are used to render more advanced disease operable. Even CRLM with low burden lung metastases can be resected in combination with lung resection, with good reported outcomes[@b2]. Where curative treatment is not possible selective internal radiation therapy (SIRT) can offer excellent palliation.

5 year survival rates following CRLM resection are reported as high as 48%[@b3]. When disease recurs the criteria for further resection remain the same, with excellent outcomes reported from repeated resection. Ultimately we are entering a new era in the management of CRLM; no longer should development of CRLM be considered a terminal event as we attempt to cure or convert this into a chronic condition.

UMJ is an open access publication of the Ulster Medical Society (<http://www.ums.ac.uk>).
